Jacquemin E
Department of Pediatrics and INSERM U 347, Bicêtre Hospital, Le Kremlin Bicêtre, France.
J Gastroenterol Hepatol. 1999 Jun;14(6):594-9. doi: 10.1046/j.1440-1746.1999.01921.x.
Progressive familial intrahepatic cholestasis (PFIC), also known as Byler disease, is an inherited disorder of childhood in which cholestasis of hepatocellular origin often presents in the neonatal period and leads to death from liver failure before adolescence. The pattern of appearance of affected children within families is consistent with autosomal recessive inheritance. Several studies have provided support for the heterogeneity of this clinical entity suggesting the existence of different types due to different disorders affecting the hepatocyte and related to defects of bile acid secretion or bile acid metabolism. Recent molecular and genetic studies have identified genes responsible for three types of PFIC and have shown that PFIC was related to mutations in hepatocellular transport system genes involved in bile formation. These findings now provide specific diagnostic tools for the investigation of children with PFIC and should allow prenatal diagnosis in the future. Genotype-phenotype correlations performed in patients treated with ursodeoxycholic acid or biliary diversion should allow those PFIC patients who could benefit from these therapies to be precisely identified. In the future, other therapies, such as cell and gene therapies, might be considered and could also represent an alternative to liver transplantation.
进行性家族性肝内胆汁淤积症(PFIC),也称为比勒氏病,是一种儿童期遗传性疾病,肝细胞源性胆汁淤积症常在新生儿期出现,并导致在青春期前死于肝功能衰竭。患病儿童在家族中的出现模式符合常染色体隐性遗传。多项研究支持了这一临床实体的异质性,表明由于影响肝细胞的不同疾病以及与胆汁酸分泌或胆汁酸代谢缺陷相关,存在不同类型。最近的分子和遗传学研究已确定了导致三种类型PFIC的基因,并表明PFIC与参与胆汁形成的肝细胞转运系统基因突变有关。这些发现现在为PFIC患儿的调查提供了特定的诊断工具,并应能在未来实现产前诊断。对接受熊去氧胆酸或胆汁转流治疗的患者进行的基因型-表型相关性研究,应能精确识别那些可从这些治疗中获益的PFIC患者。未来,可能会考虑其他治疗方法,如细胞和基因治疗,它们也可能成为肝移植的替代方案。